Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods – 8 September 2023

Overview

The Therapeutic Goods Act 1989 was enacted to provide a comprehensive framework for the regulation of therapeutic goods, including medicines, medical devices, and blood products, in Australia. This Act was introduced to address the need for a robust system to ensure that these goods are safe, of high quality, and effective for their intended use. The Therapeutic Goods Act 1989 is administered by the Therapeutic Goods Administration (TGA), an agency within the Department of Health and Aged Care, and its primary policy objective is to protect public health by regulating therapeutic goods in a manner that balances the need for innovation and access with the imperative for safety and efficacy. The Act allows the TGA to take action such as suspending the licence of manufacturers who do not meet the required standards, as evidenced by the recent publication of suspended licences for certain entities, to maintain the integrity of the therapeutic goods market.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities and individuals involved in the manufacture, supply, importation, and advertising of therapeutic goods within Australia. This includes pharmaceutical drugs, medical devices, blood products, and other health-related products. The Act's jurisdiction covers the entire Commonwealth, ensuring a unified regulatory framework across Australia. The legislation encompasses a broad range of entities such as pharmaceutical companies, medical device manufacturers, and individual health practitioners who engage in the manufacture or distribution of therapeutic goods. The Act also applies to the conduct of these entities, including quality control measures, labelling, and advertising practices. There are specific exclusions and exemptions outlined within the Act, such as those for certain low-risk medical devices and exemptions for therapeutic goods used for personal use or research purposes. The Therapeutic Goods Administration may also issue subordinate instruments that extend or restrict the application of the Act, thereby providing additional regulatory detail or addressing emerging issues in the therapeutic goods industry.

Key Provisions

The Therapeutic Goods Act 1989, as referenced in the Gazette of 8 September 2023, contains provisions under Section 41(1)(d) that empower the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration to suspend a licence for the manufacture of therapeutic goods. This legislative power allows the Secretary to suspend licences at the request of the manufacturer. The recently published Gazette entry lists three manufacturers whose licences have been suspended: Royal Adelaide Hospital Radiopharmacy, Gold Coast Laboratories Pty Ltd, and Veolia Environmental Services (Australia) Pty Ltd. The suspensions are effective for varying durations, ranging from 28 June 2023 to 30 June 2024. Under the Therapeutic Goods Act 1989, the obligations imposed on the parties affected by these suspensions include the immediate cessation of manufacturing activities as per the specified dates. The manufacturers must comply with the suspension orders and refrain from manufacturing therapeutic goods during the period of suspension. This ensures that only therapeutic goods produced under compliant conditions are available for use. The act provides a framework to maintain the quality, safety, and efficacy of therapeutic goods supplied to the public. The Therapeutic Goods Act 1989 outlines various offences and consequences for non-compliance with its provisions. Entities that continue to manufacture therapeutic goods despite a suspension of their licence can face significant penalties. Under Section 41(2) of the Act, a person who contravenes a direction to suspend a licence can be subject to both civil and criminal penalties. For civil penalties, the maximum fines are substantial, reflecting the seriousness of the public health risks involved. In criminal proceedings, offenders may face imprisonment, highlighting the gravity of the non-compliance. It is crucial for affected entities to adhere to the suspension notices to avoid these severe repercussions.